Hematology-Oncology
Latest news
316 articles · 20 / page
T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-c
Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy
This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.
Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis
This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.
Restrictive Treatment Criteria Improve Prognosis Prediction in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry
A restrictive treatment initiation approach in CLL, endorsed by the Brazilian Group of CLL, identifies patients with higher risk more accurately and spares low-risk patients from unnecessary therapy, showing superior prognostic stratificati
Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen
The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers
Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos
Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma
The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated
Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study
A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use a
Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors
Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a
UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling
This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.
VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome
This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.
Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming
Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev
Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance
A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therape
Decoding Epstein-Barr Virus Genomic Alterations: Implications for Human Malignancies and Disease Pathogenesis
A comprehensive genomic analysis of Epstein-Barr virus (EBV) reveals distinct single nucleotide and structural variations linked to various human diseases, especially hematological malignancies, highlighting viral mechanisms underlying path
Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of
Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling
This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for dis
Genetic Architecture of Myeloproliferative Neoplasm Subtypes: Uncovering a Novel Sex-Specific Association at CDH22/CD40
A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.
Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry
A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the
Prognostic Markers and Survival Outcomes in Advanced Mycosis Fungoides and Sézary Syndrome: Insights from the Cutaneous Lymphoma International Consortium
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
Browse by specialty
Open language-specific specialty feeds and department pages.